Navigation Links
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
Date:5/27/2009

;1%-33%), and hepatotoxicity (approx 5%)--and severe adverse experiences (NCI Grades 3/4), including severe fluid retention (e.g., pleural effusion, pulmonary edema, and ascites) and superficial edema (1.3%-11%), hemorrhage (1.8%-19%), and musculoskeletal pain (2%-9%) were reported among patients receiving Gleevec*. Severe fluid retention appears to be dose-related, was more common in the advanced-phase studies (where the dosage was 600 mg/day), and is more common in the elderly.

In HES/CEL patients, instances of Grade 3 leukopenia, neutropenia, lymphopenia, and anemia were reported.

For DFSP, severe (NCI Grades 3/4) lab abnormalities included anemia (17%), thrombocytopenia (17%), neutropenia (8%), and increased creatinine (8%).

In GIST, severe (NCI Grades 3/4) lab abnormalities (400 mg/day; 600 mg/day)--including neutropenia (10%; 11%), anemia (3%; 9%), thrombocytopenia (0%; 1%), and hepatotoxicity (6%; 8%)--and severe adverse experiences (NCI Grades 3/4), including severe fluid retention (eg, pleural effusion or ascites; 3%; 8%) and superficial edema (6%; 5%), hemorrhage (6%; 11%), abdominal pain (11%; 4%), nausea (6%; 4%), diarrhea (3%; 7%), and musculoskeletal pain (6%; 1%) were reported among patients receiving Gleevec.

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Dose adjustments may be necessary due to hepatotoxicity, other nonhematologic adverse reactions, or hematologic adverse reactions. Therapy with Gleevec was discontinued for drug-related adverse reaction
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
2. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
3. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
4. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
5. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
6. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
7. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
8. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
9. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
10. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
11. Video: Answer to Curing a Failing Heart May Exist in Bodys Own Do-It-Yourself Repair Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... UNION CITY, Calif. , Nov. 21, 2014 /PRNewswire/ ... products company manufacturing point-of-care instruments and consumables for the ... lab services to the veterinary and research markets in ... the completion of a stock purchase agreement to acquire ... United Kingdom based distribution organization. The ...
(Date:11/21/2014)... 21, 2014 Clementia Pharmaceuticals, ... Agency (EMA) has granted Orphan Medicinal Product ... candidate, for the treatment of fibrodysplasia ossificans ... disabling genetic disease characterized by painful, recurrent ... new abnormal bone formation. This process, known ...
(Date:11/21/2014)... YORK , Nov. 20, 2014  Market research firm ... the "Year of The Buy, in the medical device ... for medical devices will produce just 3% growth this ... actions, including acquisitions of product lines and entrance by ... annual survey of medical devices, The Global Market ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
... NEW YORK, Sept. 12, 2011 A revolutionary new ... other technology - - the VivoSight® Optical Coherence ... to dermatologists in the U.S. for the first time. ... skin surface instantly, providing additional information which will allow ...
... Sept. 12, 2011 Intarcia Therapeutics, Inc. announced ... ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) ... the 47th Annual Meeting of the European Association ...  All three presentations are scheduled for Wednesday, September ...
Cached Medicine Technology:Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 2Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 3Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 4Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 2Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 3Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes 4
(Date:11/22/2014)... November 22, 2014 In order to provide ... promotion of cocktail party dresses. The business knows that a ... social occasions. , Now, the party dresses supplier’s ... 70% off. As the leading company in fashion industry, LunaDress ... outfit for every customer. So it always raises the professional ...
(Date:11/22/2014)... Domestic farmgate milk and dairy ... due to a fall in demand for ... amid the global financial crisis. However, these declines ... dairy manufacturers on the international scene. Strong growth ... growth, primarily due to supply constraints in some ...
(Date:11/22/2014)... has been a historical time for Angeldress.co.uk, an excellent wedding ... some renowned review websites. Recently, the company has added to ... of wonderful sexy wedding dresses to its website. At the ... to an 80% discount on any order over GBP 149. ... dress at Angeldress.co.uk, which has garnered a hard core of ...
(Date:11/22/2014)... The Sports Conflict Institute is pleased to ... team of conflict resolution professionals. Baroff comes to SCI as ... has over 30 years experience as an arbitrator, educator, and ... to connect with SCI and bring my conflict resolution skills ... with a complete sports focus,” says Baroff. , “Roy has ...
(Date:11/22/2014)... Washington, DC (PRWEB) November 22, 2014 ... its monthly Tech Report , which features the ... Sofastaii, a technology expert and reporter for NewsWatch, conducted ... can easily improve the flavor of your water. , ... are everywhere. It’s important that everything is done to ...
Breaking Medicine News(10 mins):Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2Health News:SCI Announces New Team Member Roy Baroff 2Health News:SCI Announces New Team Member Roy Baroff 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2
... cent OBC quota in Central educational institutions, Union Health ... was a media creation // and that the ... ,'The resistance was all by the media,' Ramadoss ... had supported the government proposal, he said 'This is ...
... more likely to suffer from cancer and die from it, ... at Israel's //Haifa University suspect that cancers are most likely ... II. ,The researchers looked at the incidence and ... European origin - comparing those who emigrated from Europe before ...
... trying to reattach the foot of a four-year-old boy. The boy ... father // riding over him on a lawn mover. ... a lawn mower when the boy came up unexpectedly behind him. ... into reverse and accidentally ran over the boy's leg. It was ...
... women to donate their eggs for research as they ... // which they say would hopefully find new treatments ... disease. ,They want to extract embryonic stem ... patients with diabetes or neurodegenerative disease, according to Nature ...
... antibiotics for three days rather than the usual concept of ... of common pneumonia // . ,According to researchers ... antibiotic-resistant bacteria, ,Lead researcher Dr. Jan M Prins, ... in Amsterdam said,’The question is how long you should treat ...
... conducted by Dr Taraneh Dean of the University of Portsmouth and ... restricted // in their food intakes because their parents ... team found that found that 54 per cent of a sample ... their parents were convinced that such food items initiated ...
Cached Medicine News:Health News:Pneumonia Effectively Treated with Short-Term Antibiotic Course 2
... Parachute Tissue Anchor allows one step fixation of ... for arthroscopic knotless rotator cuff repair in one ... an outside thread diameter of 5 mm and ... FiberWire suspension sutures securely hold a thin, bioabsorbable ...
... The Bio-SutureTak is a 3 mm bioabsorbable ... ideal for soft tissue attachment to bone in ... small anchor profile with high pull-out strength is ... molded into the body of the anchor and ...
TigerStick is a white #2 FiberStick with black stripes and a stiffened, 12 inch, waxed end. It is especially useful when motion determination and alternating colored sutures are required in the arthr...
... MMS soon offers the Flowmaster. It is ... everyday flow studies, where ease of use, simplicity ... wireless uroflowmeter which makes it now very easy ... the flowmaster anywhere you want and data will ...
Medicine Products: